Natixis Acelrx Pharmaceuticals Inc Transaction History

Natixis

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$1.25 - $2.77 $43,750 - $96,950	-35,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$1.18 - $1.98 $41,300 - $69,300	35,000 New	35,000 $43,000
Q3 2018 Nov 14, 2018	SELL	$2.6 - $4.6 $52,000 - $92,000	-20,000 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$2.13 - $4.2 $185,310 - $365,400	-87,000 Reduced 81.31%	20,000 $68,000
Q4 2017 Feb 14, 2018	BUY	$1.75 - $5.5 $87,500 - $275,000	50,000 Added 87.72%	107,000 $232,000
Q3 2017 Nov 14, 2017	BUY	$2.9 - $4.6 $165,300 - $262,200	57,000	57,000 $260,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.